Please assess the completion status of the following clinical trial:

Trial Title: An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. cancer patients regularly experienced 1 to 3 breakthrough pain episodes per day that required additional opioids from pain control;~2. a current regimen of opioids equivalent to 60-360 mg/day of oral morphine or 25-150 mcg/hr of transdermal fentanyl for one week or longer;~3. at least partial relief of breakthrough pain by use of opioid therapy;~4. able to self-administer the study medication correctly or has an available adult caregiver to administer the study medication correctly;~5. willing and able to complete patient diary with each pain episode.~6. 20 to 80 years of age;~Exclusion Criteria:~1. rapidly escalating pain (e.g., regularly more than 3 breakthrough pain episodes per day) that are hard to be controlled by analgesics;~2. history of hypersensitivity or intolerance to fentanyl;~3. cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression;~4. psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary;~5. Severe (Grade 4) mucositis (subjects with less than severe mucositis are permitted and must be instructed to not apply the Painkyl® film at a site of inflammation);~6. abnormal oral mucosa which will impede drug absorption;~7. recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse;~8. use of an investigational drug or other rapid-onset opioids drugs within 4 weeks preceding this study;~9. pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).